210 related articles for article (PubMed ID: 18566292)
1. The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors.
Witkin JM; Levant B; Zapata A; Kaminski R; Gasior M
J Pharmacol Exp Ther; 2008 Sep; 326(3):930-8. PubMed ID: 18566292
[TBL] [Abstract][Full Text] [Related]
2. Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907].
Witkin JM; Dijkstra D; Levant B; Akunne HC; Zapata A; Peters S; Shannon HE; Gasior M
J Pharmacol Exp Ther; 2004 Mar; 308(3):957-64. PubMed ID: 14711932
[TBL] [Abstract][Full Text] [Related]
3. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
[TBL] [Abstract][Full Text] [Related]
4. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
5. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
[TBL] [Abstract][Full Text] [Related]
6. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
7. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
8. Lack of functional D2 receptors prevents the effects of the D3-preferring agonist (+)-PD 128907 on dialysate dopamine levels.
Zapata A; Shippenberg TS
Neuropharmacology; 2005 Jan; 48(1):43-50. PubMed ID: 15617726
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D3 receptor agonists partially reproduce the discriminative stimulus effects of cocaine in squirrel monkeys.
Spealman RD
J Pharmacol Exp Ther; 1996 Sep; 278(3):1128-37. PubMed ID: 8819495
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).
van Vliet LA; Rodenhuis N; Dijkstra D; Wikström H; Pugsley TA; Serpa KA; Meltzer LT; Heffner TG; Wise LD; Lajiness ME; Huff RM; Svensson K; Sundell S; Lundmark M
J Med Chem; 2000 Jul; 43(15):2871-82. PubMed ID: 10956195
[TBL] [Abstract][Full Text] [Related]
12. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907.
Witkin J; Gasior M; Acri J; Beekman M; Thurkauf A; Yuan J; DeBoer P; Wikström H; Dijkstra D
Eur J Pharmacol; 1998 Apr; 347(2-3):R1-3. PubMed ID: 9741997
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys.
Achat-Mendes C; Grundt P; Cao J; Platt DM; Newman AH; Spealman RD
J Pharmacol Exp Ther; 2010 Aug; 334(2):556-65. PubMed ID: 20494958
[TBL] [Abstract][Full Text] [Related]
15. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
[TBL] [Abstract][Full Text] [Related]
16. Modification by dopaminergic drugs of choice behavior under concurrent schedules of intravenous saline and food delivery in monkeys.
Gasior M; Paronis CA; Bergman J
J Pharmacol Exp Ther; 2004 Jan; 308(1):249-59. PubMed ID: 14563783
[TBL] [Abstract][Full Text] [Related]
17. Cocaine sensitization prevents the hypolocomotor effects of high but not low doses of PD 128,907.
Prinssen EP; Koek W; Kleven MS
Eur J Pharmacol; 1998 Aug; 355(1):19-22. PubMed ID: 9754934
[TBL] [Abstract][Full Text] [Related]
18. Chlormethiazole: effectiveness against toxic effects of cocaine in mice.
Gasior M; Ungard JT; Witkin JM
J Pharmacol Exp Ther; 2000 Oct; 295(1):153-61. PubMed ID: 10991973
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D3 agonists disrupt social behavior in rats.
Kagaya T; Yonaga M; Furuya Y; Hashimoto T; Kuroki J; Nishizawa Y
Brain Res; 1996 May; 721(1-2):229-32. PubMed ID: 8793104
[TBL] [Abstract][Full Text] [Related]
20. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
